Utility of autologous fecal microbiota transplantation and elucidation of microbiota in diversion colitis

Kentaro Tominaga1 | Atsunori Tsuchiya1 | Takeshi Mizusawa1 | Asami Matsumoto2 | Ayaka Minemura2 | Kentaro Oka2 | Motomichi Takahashi2 | Tomoaki Yoshida1 | Yuichi Kojima1 | Kohei Ogawa1 | Yuzo Kawata1 | Nao Nakajima1 | Naruhiro Kimura1 | Hiroyuki Abe1 | Toru Setsu1 | Kazuya Takahashi1 | Hiroki Sato1 | Satoshi Ikarashi1 | Kazunao Hayashi1 | Ken-ichi Mizuno1 | Junji Yokoyama1 | Yosuke Tajima3 | Masato Nakano3 | Yoshifumi Shimada3 | Hitoshi Kameyama3 | Toshifumi Wakai3 | Shuji Terai1

1 Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
2 R&D Division, Miyarisan Pharmaceutical Co. Ltd., Saitama, Japan
3 Division of Digestive and General Surgery, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan

Correspondence
Atsunori Tsuchiya and Shuji Terai, Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1–757 Asahimachi-dori, Chuo-ku, Niigata 9518510, Japan. Email: atsunori@med.niigata-u.ac.jp; terais@med.niigata-u.ac.jp

Funding information
Takeda Japan Medical Office, Grant/Award Number: Research Grant 2018; Tsukada Medical Funded Research Grant; Grant-in-Aid for Young Scientific Research from the Ministry of Education, Science, Technology, Sports, Grant/Award Number: 19K17393

Abstract
Objectives: Diversion colitis (DC) is an inflammatory disorder caused by interruption of the fecal stream and subsequent nutrient deficiency from luminal bacteria. The utility of fecal microbiota transplantation (FMT) for DC was recently investigated; however, the precise pathogenesis of this condition remains unclear. This study aimed to evaluate the utility of autologous FMT in DC and to determine the related changes in the intestinal microbiota.

Methods: Autologous FMT was performed to reestablish the intestinal microbiota in five patients (average age, 64.6 ± 8.3 years) with DC. They underwent double-ended colostomy. We assessed the diverted colon by endoscopy and evaluated the microbiota before and after FMT using the 16S rRNA gene sequencing method.

Results: All five patients had mild inflammation (ulcerative colitis endoscopic index of severity [UCEIS] 2–3) in the diverted colon based on the colonoscopic findings. Three patients presented with symptoms, such as tenesmus, mucoid stool, and bloody stool. With FMT treatment, all patients achieved endoscopic remission (UCEIS score of 0 or 1) and symptomatic improvement. We observed a significantly decreased α-diversity in DC patients compared to healthy controls. The frequency of aerobic bacteria, such as Enterobacteriaceae, in the diverted colon decreased after autologous FMT.

Conclusions: This study was the first to show that the microbiota in the diverted colon was significantly affected by autologous FMT. Since interruption of the fecal stream is central to the development of DC, FMT can be considered a promising treatment.

KEYWORDS
colostomy, diversion colitis, Enterobacteriaceae, fecal microbiota transplantation, intestinal microbiota
INTRODUCTION

Diversion colitis (DC) was first described by Morson and Dawson in 1934 as nonspecific inflammation of the diverted colon. Glotzer et al. termed this inflammation “DC” in 1981. A prospective study showed that colitis was detected via endoscopic studies on patients who underwent colostomy 3–36 months prior. Approximately one third of DC patients had symptoms, such as abdominal discomfort, tenesmus, mucoid discharge, and rectal bleeding. The change in the microbiota of the diverted colon was reportedly a major cause of DC; however, the precise pathogenesis of this condition remains unclear. Gundling et al. first reported a successful autologous fecal transplantation in a patient with chronic DC. We have previously reported a case with clinical findings of DC and microbiota in a diverted ileal pouch before and after autologous fecal microbiota transplantation (FMT). We also previously reported on the microbiota, intestinal short-chain fatty acids, and immunoglobulin A (IgA) in the diverted colon in eight patients who underwent colostomies. In the present study, five of these eight patients underwent autologous FMT, and we compared the endoscopic findings and intestinal microbiota before and after the treatment. This present study aimed to evaluate the utility of autologous FMT and to determine the changes in the intestinal microbiota of DCs.

METHODS

Subjects and study protocol

Written informed consent was obtained from the patients for the publication of the report and accompanying images. We also obtained written informed consent from the patients to receive auto FMT and provide stool samples. The study (including the informed consent for collecting fecal samples from healthy individuals) was reviewed and approved by the Institutional Review Board of Niigata University (2017-0154). The subjects were five patients (64.6 ± 8.3 years) (male:female = 0:5) who underwent colostomy within the previous 6–40 months. Two of these patients had a history of rectal cancer, while the remaining three patients had a retroperitoneal abscess, ovarian cancer, and rectovaginal septum cancer, respectively (Table 1). We assessed the diverted colon endoscopically and evaluated its severity using the ulcerative colitis endoscopic index of severity (UCEIS). None of the patients received antibiotics or probiotics for 1 month leading up to the date of colonoscopy. Furthermore, none of the patients had previously undergone enema with short-chain fatty acids, mesalazine, or corticosteroids for DC. We performed autologous FMT to reestablish the intestinal microbiota for these patients. We injected 10–20 ml of saline-diluted autologous feces from the stoma to the diverted colon using a Nelaton catheter. Nine FMTs were performed for over 4 weeks (when changing the stoma pouch once every 3 days) (Figure 1a).

We assessed the intestinal microbiota of the diverted colon using a next-generation sequencer (Illumina MiSeq; Illumina, San Diego, CA, USA). We conducted a 16S rRNA gene sequence analysis. The composition of the intestinal microbiota was evaluated using quantitative insights on microbial ecology. To evaluate diversity, feces from six healthy individuals (38.5 ± 3.4 years) (male:female = 4:2) were used as controls. Data on the intestinal microbiota in the diverted colon before and after FMT treatment were analyzed using the linear discriminant analysis (LDA) effect size.

Intestinal sample collection

We collected the intestinal samples from the diverted colon (the rectum) using net forceps endoscopically without a biopsy. Intestinal samples (approximately 100 mg) were suspended in 900 μl of guanidine thiocyanate solution (100 mM Tris–HCl [pH 9.0], 40 mM EDTA, and 4 M guanidine thiocyanate) and frozen at −80°C until further analysis.

DNA preparations from intestinal samples

The collected samples were sent to the laboratory of Miyarisan Pharmaceutical Co. Ltd. and stored at 4°C.
DNA was extracted from collected intestinal samples using a bead beating method and purified, according to a previously reported method. The amount of DNA was determined using the Quanti Fluor ONEEdsDNA System and Quantus Fluorometer (Promega, Madison, WI, USA).

**PCR amplification and analysis of 16S rRNA gene sequence**

The V3-V4 region of the 16S rRNA gene was polymerase chain reaction (PCR) amplified from stool DNA samples using a TaKaRa Ex Taq Hot Start PCR mixture (Takara Bio, Shiga, Japan). The primers used for PCR amplification were 341F and 785R, which contained the Illumina index and sequencing adapter overhangs. PCR assays were performed using a TaKaRa PCR Thermal Cycler Dice Touch device (Takara Bio) with the following parameters: initial denaturation at 98°C for 30 s, followed by 35 cycles of 98°C for 10 s, and 60°C for 30 s, with a final extension step at 72°C for 5 min. The PCR products were purified, and size was selected using SPRIselect (Beckman Coulter, Brea, CA, USA). DNA concentrations were quantified with a QuantiFluor ONEEdsDNA System and Quantus Fluorometer (Promega), and equal amounts of purified PCR products were pooled for subsequent Illumina MiSeq sequencing. Sequencing was carried out with a Miseq Regent Kit V3 (600 cycles) (Illumina), according to the manufacturer’s instructions. Sequence processing and quality assessment were performed using the QIIME package (version 1.9.1) (http://qiime.org), open-source software created to address the problem of obtaining sequencing data from raw sequences for interpretation and database deposition. To obtain an overall diversity analysis for subsequent comparative and statistical evaluations, we merged the biological observation matrix (BIOM) tables provided by QIIME into a unique BIOM table using a script included in the QIIME package. Paired-end reads were merged using the Fastq-join script in ea-utils with the parameters \( m = 6 \) and \( p = 20 \) and then quality-filtered using QIIME’s script split_libraries_fastq.py \( (r = 3, p = 0.75, q = 20, n = 0) \). De novo and reference-based chimera detection and removal were performed using USEARCH v6.1 with the Greengenes v13.8 database. Operational taxonomic units (OTUs) were chosen using an open reference OTU-picking pipeline against the 97% identity of the pre-clustered Greengenes v13.8 database using UCLUST. According to the manufacturer, the QIIME alpha diversity analysis script is used to perform rarefaction analysis by subsampling the OTU biom table on the basis of the minimum rarefaction depth value chosen by the user depending on the minimum number of sequences/samples obtained. For our subset, this value was 16087. Then, using different metrics, alpha diversity was computed for each rarefied OTU table. We used two non-phylogeny-based metrics: Chao 1 and the Observed_OTUs. After performing the rarefaction evaluation, the QIIME beta diversity analysis script was used to compute beta diversity with the rarefied OTUs table using different metrics. We used phylogeny-based metrics (unweighted and weighted UniFrac). Finally, the script was used to obtain a distance metric to compute the principal coordinate analysis (PCoA) and convert it into plots for the visualization of results.
We used permutational multivariate analysis of variance (PERMANOVA) to evaluate the statistical significance of beta diversity distances.

**Statistical analysis**

The alpha-diversity indices were compared between the groups using the Mann–Whitney U test in R (The R Foundation for Statistical Computing, Vienna, Austria). The significance of beta-diversity was evaluated by PERMNOVA in QIIME 1.9.1. The enriched bacteria in each group were identified by LDA effect size (LEfSe)\(^{15}\); LDA values >3 were considered significant.

**RESULTS**

**Endoscopic evaluation and symptoms**

Five patients underwent stoma surgery within 6–40 months prior to this study. Since the method for assessing inflammation of DC has not yet been established, we performed endoscopy for all patients and evaluated the inflammation of the diverted colon using the UCEIS score.\(^{9}\) All five patients had mild inflammation (UCEIS score 2 or 3), such as erythema and mucosal friability, as detected via endoscopy (Table 1). We could detect mucosal bleeding and blurring of vascular pattern in all five patients and erosions in two patients. With autologous FMT treatment, all patients achieved endoscopic remission (UCEIS score 0 or 1) at 1 month after the treatment (Figure 1b).

Three of the five patients showed symptoms, such as tenesmus, mucus, or bloody stools (Table 1). Two patients had no obvious symptoms at the time of endoscopy, but sometimes had tenesmus and mucous stools during the 6 months after surgery. Taking the inflammatory findings of the endoscopy into consideration, FMT treatment was performed with the patient's consent to prevent symptom recurrence. With autologous FMT treatment, all patients achieved symptomatic improvement within 2 weeks of starting FMT. No adverse effects of autologous FMT were observed.

**Intestinal microbiota**

We analyzed the intestinal microbiota using 16S rRNA gene sequencing and detected significantly decreased alpha-diversity (Observed OTUs and chao1, \(p < 0.01\); the data were analyzed using the Mann–Whitney U test) in DC patients compared to healthy controls (Figure 2a). These results indicate that the intestinal microbiota...
of DC patients is less diverse than that of young healthy individuals (control). Regarding the $\beta$-diversity, clusters were formed in DC patients and healthy controls (Figure 2b). The $\beta$-diversity also showed a significant difference between DC patients and healthy controls (weighted and unweighted UniFrac, $p < 0.01$; the data were analyzed using the PERMANOVA), which indicated a low similarity of microbiota between the two groups.

We analyzed the intestinal microbiota in the diverted colon before and after FMT treatment using the LDA effect size. The analysis of the intestinal microbiota at the genus level showed a significantly decreased frequency of Enterobacteriaceae in the diverted colon after FMT treatment compared to before FMT (Figure 3a). After the treatment, in addition to the significantly decreased frequency of Enterobacteriaceae at the genus level, the frequency of Enterobacteriaceae at the family level, Enterobacteriales at the order level, and Gamma-proteobacteria at the class level were also significantly decreased (Figure 3b). Moreover, there was a significantly increased frequency of Clostridiaceae at the genus level after treatment (Figure 3b).

**DISCUSSION**

The prospective study reported that almost all cases exhibited colitis, based on the endoscopic findings, at 3–36 months after the colostomy. These findings include erythema, diffuse granularity, and blurring of vascular pattern in approximately 90% of the population. It is also associated with mucosal friability (80%), edema (60%), aphthous ulceration, and bleeding, to varying degrees. The UCEIS score is often used to evaluate endoscopic findings in DC. In our study, mild colitis (UCEIS score 2 or 3) was observed in all patients endoscopically at 6–40 months after the colostomy.

Re-anastomosis was proven to be consistent and effective for DC. Non-surgical treatments, including antibiotics, glucocorticoids, short-chain fatty acid enemas, and 5-aminosalicylic acid, are viable alternatives.
Gundling et al. first reported that autologous FMT was an effective and safe option for relapsing DCs after the standard therapies have failed. Few cases have reported the utility of autologous FMT for DC. In this study, the method of administration was determined according to the state of inflammation with reference to our case. Unlike existing methods, an endoscope is not required, and there is no need to stay in bed for a long time after FMT treatment. This study showed that administering a small amount of feces to the diverted colon during stoma replacement reduced inflammation and relieved symptoms. Autologous FMT was safe and inexpensive with a low risk of complications.

The interruption of the fecal stream is central to the development of DC. Baek et al. reported decreased anaerobes, such as Lactobacillus and Bifidobacterium, in DC. We have reported the microbiota in DCs. The microbiota showed a change in the proportion of some species, especially Lactobacillus, which was significantly decreased in the diverted colon. We also showed that intestinal short-chain fatty acids were significantly decreased, and intestinal IgA was significantly increased in the diverted colon. Our results suggested that short-chain fatty acids affected the microbiota, such as Lactobacillus, which plays a role in the immunity of the diverted colon. However, the changes in the intestinal microbiota after FMT remain unknown. In the present study, we observed a significantly decreased frequency of aerobic bacteria, such as Enterobacteriaceae, and a significantly increased frequency of anaerobic bacteria, such as Clostridiaceae, after autologous FMT in the diverted colon. Neut et al. reported that the aerobic bacteria increased in the diverted colon and are a major cause of DC, which is similar to our findings.

A decreased diversity of intestinal microbiota has been noted in patients with inflammatory bowel diseases, such as ulcerative colitis or Crohn’s disease. However, there are no reports on the diversity of intestinal microbiota in patients with DC. In our study, we found a decrease in the α-diversity of intestinal microbiota in patients with DC compared with healthy controls. We also showed a significant difference in β-diversity between the two groups. These results indicate that the intestinal microbiota of DC patients forms different clusters and is less diverse than that of healthy controls. As a limitation, further research is needed due to the small number of cases and bias by age and gender. Follow-up information would also be important, but since all five patients underwent stoma closure within 2 weeks after FMT treatment, subsequent long-term follow-up and endoscopic evaluation were not possible. We believe that further studies are necessary.

This was the first report to show significant changes in the intestinal microbiota before and after autologous FMT in DC patients. Since DC can be resolved by reestablishing the microbiota, autologous FMT is a viable treatment option.

In conclusion, autologous FMT resulted in a change in the microbiota, followed by improvement of symptoms and colonoscopy findings. Further studies are necessary to elucidate the mechanisms behind DC. Fecal stream interruption is central to DC development. Our study emphasized the significance of autologous FMT as a means of safely reestablishing the microbiota in DC.

**ACKNOWLEDGEMENT**
The authors would like to thank Miyarisan Pharmaceutical Co. Ltd. for their cooperation.

**CONFLICT OF INTEREST**
Miyarisan Pharmaceutical Co. Ltd. supported this study in the analysis of the microbiota.

**FUNDING INFORMATION**
The present study has received financial support from Takeda Japan Medical Office Funded Research Grant 2018, Tsukada Medical Funded Research Grant, Grant-in-Aid for Young Scientific Research (19K17393) from the Ministry of Education, Science, Technology, Sports, and Miyarisan Pharmaceutical Co. Ltd.

**ORCID**
Kentaro Tominaga https://orcid.org/0000-0001-6792-1005
Motomichi Takahashi https://orcid.org/0000-0003-4773-5904
Satoshi Ikarashi https://orcid.org/0000-0001-7271-7762

**REFERENCES**
1. Morson BC, Dawson IMP. *Gastrointestinal pathology*. 1st ed. London: Blackwell; 1998.
2. Glotzer DJ, Glick ME, Goldman H. Proctitis and colitis following diversion of the fecal stream. *Gastroenterology* 1981; **80**: 438–41.
3. Korelitz BI, Cheskin LJ, Sohn N, Sommers SC. Proctitis after fecal diversion in Crohn’s disease and its elimination with reanastomosis: Implications for surgical management. Report of four cases. *Gastroenterology* 1984; **87**: 710–3.
4. Szczepkowski M, Kobus A, Borycka K. How to treat diversion colitis?–Current state of medical knowledge, own research and experience. *Acta Chir Iugosl* 2008; **55**: 77–81.
5. Ma CK, Gottlieb C, Haas PA. Diversion colitis: A clinicopathologic study of 21 cases. *Hum Pathol* 1990; **21**: 429–36.
6. Tominaga K, Kamimura K, Takahashi K, Yokoyama J, Yamagiwa S, Terai S. Diversion colitis and pouchitis: A mini-review. *World J Gastroenterol* 2018; **24**: 1734–47.
7. Gundling F, Tiller M, Agha S, Scheppe W, Lescaliers I. Successful autologous fecal transplantation for chronic diversion colitis. *Tech Coloproctol* 2015; **19**: 51–2.
8. Tominaga K, Tsuchiya A, Yokoyama J, Terai S. How do you treat this diversion ileitis and pouchitis? *Gut* 2019; **68**: 593–758.
9. Tominaga K, Tsuchiya A, Mizusawa T, Terai S. Evaluation of intestinal microbiota, short-chain fatty acids, and immunoglobulin A in diversion colitis. *Biochem Biophys Rep* 2021; **25**: 100892.
10. Nishimoto Y, Mizutani S, Nakajima T, *et al*. High stability of faecal microbiome composition in guanidine thiocyanate solution at
11. Jin JS, Touyama M, Yamada S, Yamazaki T, Benno Y. Alteration of a human intestinal microbiota under extreme life environment in the Antarctica. *Biol Pharm Bull* 2014; 37: 1899–906.

12. Klindworth A, Pruesse E, Schweer T, et al. Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies. *Nucleic Acids Res* 2013; 41: e1.

13. Kuczynski J, Stombaugh J, Walters WA, González A, Caporaso JG, Knight R. Using QIIME to analyze 16S rRNA gene sequences from microbial communities. *Curr Protoc Bioinformatics*. 2011; 7: 1–28.

14. Parks DH, Beiko RG. Measuring community similarity with phylogenetic networks. *Mol Biol Evol* 2012; 29: 3947–58.

15. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. *Genome Biol* 2011; 12: R60.

16. Roe AM, Warren BF, Brodribb AJ, Brown C. Diversion colitis and involution of the defunctioned anorectum. *Gut* 1993; 34: 382–5.

17. Geraghty JM, Talbot IC. Diversion colitis: Histological features in the colon and rectum after defunctioning colostomy. *Gut* 1991; 32: 1020–3.

18. Kalla R, Pitt M, Sharma A. The role of autologous fecal microbiota transplantation in diversion colitis: A case report. *Inflamm Bowel Dis* 2019; 25: e29–30.

19. Baek SJ, Kim SH, Lee CK, et al. Relationship between the severity of diversion colitis and the composition of colonic bacteria: A prospective study. *Gut Liver* 2014; 8: 170–6.

20. Neut C, Colombel JF, Guillemot F, et al. Impaired bacterial flora in human excluded colon. *Gut* 1989; 30: 1094–8.

21. Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. *Inflamm Bowel Dis* 2007; 13: 955–62.

22. Andoh A, Kuzuoka H, Tsujikawa T, et al. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. *J Gastroenterol* 2012; 47: 1298–307.